PortfoliosLab logoPortfoliosLab logo
GSK vs. HEI
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GSK vs. HEI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GlaxoSmithKline plc (GSK) and HEICO Corporation (HEI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GSK achieves a 4.91% return, which is significantly higher than HEI's 0.01% return. Over the past 10 years, GSK has underperformed HEI with an annualized return of 4.64%, while HEI has yielded a comparatively higher 25.42% annualized return.


GSK

1D
-1.71%
1M
1.25%
YTD
4.91%
6M
6.15%
1Y
27.36%
3Y*
17.87%
5Y*
4.68%
10Y*
4.64%

HEI

1D
-2.39%
1M
10.59%
YTD
0.01%
6M
2.87%
1Y
6.72%
3Y*
25.63%
5Y*
17.50%
10Y*
25.42%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GSK vs. HEI - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GSK
GlaxoSmithKline plc
4.91%51.23%-5.14%9.71%-33.41%26.74%-17.72%29.24%13.79%-2.97%
HEI
HEICO Corporation
0.01%36.22%33.05%16.56%6.67%9.06%16.16%47.54%28.51%53.04%

Correlation

The correlation between GSK and HEI is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.20

Correlation (3Y)
Calculated over the trailing 3-year period

0.14

Correlation (5Y)
Calculated over the trailing 5-year period

0.17

Correlation (10Y)
Calculated over the trailing 10-year period

0.17

Correlation (All Time)
Calculated using the full available price history since Mar 18, 1992

0.19

Fundamentals

Market Cap

GSK:

$103.15B

HEI:

$45.63B

EPS

GSK:

$2.85

HEI:

$5.60

PE Ratio

GSK:

17.78

HEI:

57.77

PEG Ratio

GSK:

1.19

HEI:

2.60

PS Ratio

GSK:

3.16

HEI:

9.29

PB Ratio

GSK:

4.38

HEI:

8.46

Total Revenue (TTM)

GSK:

$32.78B

HEI:

$4.91B

Gross Profit (TTM)

GSK:

$23.87B

HEI:

$943.00M

EBITDA (TTM)

GSK:

$11.30B

HEI:

$1.12B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GSK vs. HEI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GSK
GSK Risk / Return Rank: 6969
Overall Rank
GSK Sharpe Ratio Rank: 7373
Sharpe Ratio Rank
GSK Sortino Ratio Rank: 6868
Sortino Ratio Rank
GSK Omega Ratio Rank: 6565
Omega Ratio Rank
GSK Calmar Ratio Rank: 7070
Calmar Ratio Rank
GSK Martin Ratio Rank: 6969
Martin Ratio Rank

HEI
HEI Risk / Return Rank: 4747
Overall Rank
HEI Sharpe Ratio Rank: 4949
Sharpe Ratio Rank
HEI Sortino Ratio Rank: 4545
Sortino Ratio Rank
HEI Omega Ratio Rank: 4444
Omega Ratio Rank
HEI Calmar Ratio Rank: 4848
Calmar Ratio Rank
HEI Martin Ratio Rank: 4949
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GSK vs. HEI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and HEICO Corporation (HEI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GSKHEIDifference
Sharpe ratioReturn per unit of total volatility

+0.82

Sortino ratioReturn per unit of downside risk

+1.03

Omega ratioGain probability vs. loss probability

1.19

1.07

+0.12

Calmar ratioReturn relative to maximum drawdown

1.48

0.25

+1.23

Martin ratioReturn relative to average drawdown

3.38

0.60

+2.78

GSK vs. HEI - Sharpe Ratio Comparison

The current GSK Sharpe Ratio is 1.02, which is higher than the HEI Sharpe Ratio of 0.21. The chart below compares the historical Sharpe Ratios of GSK and HEI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


GSKHEIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.02

0.21

+0.82

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.19

0.64

-0.45

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.20

0.83

-0.63

Sharpe Ratio (All Time)

Calculated using the full available price history

0.32

0.51

-0.19

Drawdowns

GSK vs. HEI - Drawdown Comparison

The maximum GSK drawdown since its inception was -55.70%, smaller than the maximum HEI drawdown of -75.50%. Use the drawdown chart below to compare losses from any high point for GSK and HEI.


Loading charts...

Drawdown Indicators


GSKHEIDifference

Max Drawdown

Largest peak-to-trough decline

-55.70%

-75.50%

+19.80%

Max Drawdown (1Y)

Largest decline over 1 year

-18.63%

-27.11%

+8.48%

Max Drawdown (3Y)

Largest decline over 3 years

-28.46%

-27.11%

-1.35%

Max Drawdown (5Y)

Largest decline over 5 years

-50.10%

-27.11%

-22.99%

Max Drawdown (10Y)

Largest decline over 10 years

-50.10%

-57.73%

+7.63%

Current Drawdown

Current decline from peak

-15.91%

-9.65%

-6.26%

Average Drawdown

Average peak-to-trough decline

-18.87%

-19.96%

+1.09%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.11%

11.14%

-3.03%

Volatility

GSK vs. HEI - Volatility Comparison

The current volatility for GlaxoSmithKline plc (GSK) is 6.42%, while HEICO Corporation (HEI) has a volatility of 13.61%. This indicates that GSK experiences smaller price fluctuations and is considered to be less risky than HEI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GSKHEIDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.42%

13.61%

-7.19%

Volatility (6M)

Calculated over the trailing 6-month period

18.51%

27.21%

-8.70%

Volatility (1Y)

Calculated over the trailing 1-year period

26.94%

32.79%

-5.85%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

25.06%

27.59%

-2.53%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

22.89%

30.61%

-7.72%

Dividends

GSK vs. HEI - Dividend Comparison

GSK's dividend yield for the trailing twelve months is around 3.41%, more than HEI's 0.07% yield.


PositionTTM20252024202320222021202020192018201720162015
GSK
GlaxoSmithKline plc
3.41%3.42%4.60%3.75%5.47%4.99%5.59%4.35%5.65%5.83%6.86%5.93%
HEI
HEICO Corporation
0.07%0.07%0.09%0.11%0.12%0.12%0.12%0.12%0.14%0.08%0.22%0.28%

Financials

GSK vs. HEI - Financials Comparison

This section allows you to compare key financial metrics between GlaxoSmithKline plc and HEICO Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B10.00B20222023202420252026
7.63B
1.38B
(GSK) Total Revenue
(HEI) Total Revenue
Values in USD except per share items

GSK vs. HEI - Profitability Comparison

The chart below illustrates the profitability comparison between GlaxoSmithKline plc and HEICO Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-40.0%-20.0%0.0%20.0%40.0%60.0%80.0%20222023202420252026
75.4%
-33.1%
Portfolio components
GSK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.

HEI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, HEICO Corporation reported a gross profit of -454.96M and revenue of 1.38B. Therefore, the gross margin over that period was -33.1%.

GSK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.

HEI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, HEICO Corporation reported an operating income of 350.44M and revenue of 1.38B, resulting in an operating margin of 25.5%.

GSK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.

HEI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, HEICO Corporation reported a net income of 233.80M and revenue of 1.38B, resulting in a net margin of 17.0%.


Frequently Asked Questions


GSK and HEI have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

HEI has higher volatility (13.61%) compared to GSK (6.42%). In terms of maximum drawdown, GSK dropped -55.70% vs HEI's -75.50%.

GSK currently has the higher Sharpe Ratio (1.02 vs 0.21), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GSK and HEI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer